In a recent video interview, Amar Kishan, M.D., discussed a new study that demonstrated significant side effect reduction when utilizing magnetic resonance imaging (MRI) guidance instead of computed tomography (CT) guidance for stereotactic body radiation therapy (SBRT) to treat localized prostate cancer.
Emerging research suggests that magnetic resonance imaging (MRI) guidance may be more advantageous than computed tomography (CT) guidance for reducing the side effects of stereotactic body radiation therapy (SBRT) in the treatment of prostate cancer.
Results from the phase 3 randomized trial, recently published in JAMA Oncology, showed that MRI guidance for SBRT led to a significantly reduced acute grade 2 or greater genitourinary (GU) toxicity rate (24.4 percent) versus that of CT guidance (43.4 percent). Researchers also noted no acute grade 2 or greater gastrointestinal (GI) toxic effects with MRI guidance in comparison to a 10.5 percent toxicity rate for CT guidance.
In a recent video interview, lead study author Amar Kishan, M.D. called the MRIdian LINAC (ViewRay) a “major technological breakthrough” that allows physicians to combine continuous MRI imaging with a more targeted radiation delivery system for prostate cancer.
“(With) these advanced precision and accuracy capabilities, particularly that high degree of tracking during the treatment, we felt we could reduce the margins around the prostate that we need to treat from four millimeters to two millimeters,” explained Dr. Kishan, an associate professor, vice-chair of Clinical and Translational Research and chief of the Genitourinary Oncology Service within the Department of Radiation Oncology at UCLA.
For more insights from Dr. Kishan, watch the video below.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.